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Before the advent of tomographic imaging, it was postulated that decay of 90Y to the 0+
excited state of 90Zr may result in emission of a positron–electron pair. While the branching
ratio for pair-production is small (~32×10−6), PET has been successfully used to image 90Y
in numerous recent patients and phantom studies. 90Y PET imaging has been performed on
a variety of PET/CT systems, with and without time-of-flight (TOF) and/or resolution recov-
ery capabilities as well as on both bismuth-germanate and lutetium yttrium orthosilicate
(LYSO)-based scanners. On all systems, resolution and contrast superior to bremsstrahlung
SPECT has been reported. The intrinsic radioactivity present in LYSO-based PET scanners
is a potential limitation associated with accurate quantification of 90Y. However, intrinsic
radioactivity has been shown to have a negligible effect at the high activity concentrations
common in 90Y radioembolization. Accurate quantification is possible on a variety of PET
scanner models, with or withoutTOF, althoughTOF improves accuracy at lower activity con-
centrations. Quantitative 90Y PET images can be transformed into 3-dimensional (3D) maps
of absorbed dose based on the premise that the 90Y activity distribution does not change
after infusion. This transformation has been accomplished in several ways, although the
most common is with the use of 3D dose-point-kernel convolution. From a clinical stand-
point, 90Y PET provides a superior post-infusion evaluation of treatment technical success
owing to its improved resolution. Absorbed dose maps generated from quantitative PET
data can be used to predict treatment efficacy and manage patient follow-up. For patients
who receive multiple treatments, this information can also be used to provide patient-
specific treatment-planning for successive therapies, potentially improving response. The
broad utilization of 90Y PET has the potential to provide a wealth of dose–response infor-
mation, which may lead to development of improved radioembolization treatment-planning
models in the future.
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INTRODUCTION
Yttrium-90 (90 Y) has many properties that make it an ideal
radionuclide for targeted internal therapy. It is one of a handful of
radionuclides that is considered to be a pure β-emitter, emitting
no gamma rays at any appreciable yield following decay. 90 Y also
releases a higher energy electron than other pure β-emitters that
have been used in internal therapy, with a maximum and average
energy of 2.28 and 0.934 MeV, respectively. While 90 Y has found
broad utility in targeted internal therapies ranging from radioim-
munotherapy for non-Hodgkin’s lymphoma to radioembolization
for hepatic malignancy, it is radioembolization that benefits most
from the relatively high-energy of the 90 Y β-emission. The range
of the maximum energy 90 Y β-particle is 11 mm in tissue, while
its average energy β has a range slightly <4 mm. The penetration
depth of the high-energy 90 Y β-particle is a key component of
this radionuclide’s success in radioembolization, allowing for high
dose deposition into the tissues between embolized capillaries.
As a pureβ-emitter, 90 Y radioembolization has the advantage of
a negligible radiation burden to both non-embolized portions of
the liver and extra-hepatic tissues. Further, patients can be released
shortly after treatment with minimal precautions due to both the
lack of appreciable gamma emissions and the lack of free 90 Y,
which may be transferred to others by exposure to body fluid.
Unfortunately, these benefits come at a cost, as conventional direct
imaging of this radionuclide is not possible.
The standard-of-care post-treatment imaging of 90 Y radioem-
bolization is indirect imaging using bremsstrahlung SPECT with
a wide energy window. Despite its common use, this method
presents a number of drawbacks. Namely, the image quality pro-
duced by 90 Y bremsstrahlung SPECT is lower than that pro-
duced from conventional SPECT imaging radiotracers. Quantifi-
cation of bremsstrahlung SPECT images also requires specialized
techniques (1–3), making it impractical in the typical clinical
setting.
Recently, PET has been identified as a new method of directly
visualizing the activity distribution of 90 Y radioembolization.
Imaging is based on a minor decay branch of 90 Y resulting in
the generation of annihilation photons.
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Table 1 | Published 90Y PET phantom imaging summary.
Reference Scanner Detector
material
Reconstruction
parameters
Count-rate
linearitya (GBq)
Resolution (mm)
Lhommel et al. (13) Philips Gemini TF LYSO 2i33s, TOF, RRb 2.2 –
Werner et al. (14) Siemens BioGraph Hi-Rez 16 LSO 8i16s – 6.4
van Elmbt et al. (15) Philips Gemini TF LYSO 3i8s, TOF 2.3 9.3
van Elmbt et al. (15) Philips Gemini Power 16 GSO 3i8s, 8 mm Gaussian filter 2.3 10.0
van Elmbt et al. (15) Siemens Ecat Exact HRb BGO 3i8s, 8 mm Gaussian filter 1.2 10.6
Willowson et al. (16) Siemens BioGraph mCT LSO 1i21s, TOF, RR 4.6 –
Bagni et al. (17) GE Discovery ST BGO 2i15s, RR 2.0 6.5
D’Arienzo et al. (18) GE Discovery ST BGO 3i – 5.0
Elschot et al. (19) Siemens BioGraph mCT LSO 3i21s, TOF, RR – –
Kao et al. (20) GE Discovery 690 LYSO 3i18s, TOF, RR 3.2 10.0
aCount-rate linearity found up to the total 90Y activity listed.
bApplied post-reconstruction using a non-vendor supplied method.
PHYSICS BEHIND 90 Y AND EMISSION OF ANNIHILATION
PHOTONS
In 1955, Johnson et al. (4) and Ford (5) independently found evi-
dence of a 0+ first excited state in 90Zr, albeit in different ways.
Ford (5) predicted this state theoretically, while Johnson et al. (4)
measured the positron emission resulting from the de-excitation
of this state experimentally using a magnetic spectrometer. Decay
of 90 Y to the first excited state of 90Zr 0+ occurs rarely, but
will result in subsequent de-excitation of 90Zr with several differ-
ent possible emissions. A monopole transition of 90Zr 0+→ 0+
occurs by either the emission of a monoenergetic 1.75-MeV con-
version electron or, because the energy of the 90Zr 0+ excited state
exceeds 1.022 MeV, by internal pair-production (6, 7). Unlike typ-
ical excited states, in a 0+→ 0+monopole transition the emission
of a gamma ray is absolutely forbidden (6).
Following publication of Johnson’s findings (4), Greenberg and
Deutsch (8) used a magnetically focused coincidence detector
to accurately describe the ratio for positron emission of several
β-radionuclides that were traditionally considered to be pure β-
emitters. Greenberg determined the branching ratio for positron
emission of 90 Y to be 36± 0.9× 10−6.
More recently, Selwyn et al. (9) was able to experimentally
determine the 90 Y branching ratio for positron emission with
more accuracy than previous reports. A high purity coaxial ger-
manium detector was used along with Monte Carlo modeling
to identify the annihilation peak, and subtract out both the
bremsstrahlung and environmental background (9). Selwyn iden-
tified the probability of positron emission per decay of 90 Y to be
31.86± 0.47× 10−6 (9).
A more detailed explanation of the physics of positron emis-
sion resulting from the 90Zr 0+→ 0+ transition is given by
D’Arienzo (10).
FIRST IMAGES
While the presence of a 90Zr 0+ excited state and resultant
minor branch for positron emission following decay of 90 Y
has been known for over half of a century, coincidence imag-
ing has been performed only in the past few years. In 2004,
Nickles et al. (11) performed a quantitative measurement of
annihilation photons emitted from a 90 Y source using a sodium-
iodide scintillation detector pair operating in fast coincidence.
The small branching ratio of 90 Y was measured with high pre-
cision with a trues:randoms ratio of 1000:1. Nickles also obtained
some of the first phantom images with a micro-Derenzo phan-
tom filled with a 50-MBq/mL 90 Y activity concentration on
a Concorde microPET scanner. The scanner’s excellent reso-
lution easily resolved phantom objects as small as 1.6 mm in
size. While the true-coincidence count-rate measured by Nick-
les was low, he proposed that 90 Y coincidence imaging may prove
clinically useful due to the possibility of accurate post-infusion
quantification (11).
In 2009, Lhommel et al. (12) performed one of the first
post-infusion clinical 90 Y PET/CT scans. Images were acquired
using a Phillips Gemini Time-of-flight (TOF) system. A 2.5-mm
thick copper ring was fabricated and placed over the detectors
to decrease the count-rate from lower energy bremsstrahlung
and prevent detector saturation. Qualitative comparison with
bremsstrahlung SPECT showed superior resolution and a micros-
phere distribution that closely matched areas of high metabolic
uptake seen on 18 FDG PET/CT imaging.
Following these two preliminary reports describing the possible
viability of 90 Y PET/CT imaging, multiple authors have presented
results from both patient and phantom imaging obtained on many
different scanner types. Table 1 summarizes the PET/CT systems
used in selected phantom studies from the literature.
CONFOUNDING FACTORS
90 Y is a poor PET radiotracer when compared to those routinely
used for diagnostic purposes. Aside from the low true-coincidence
count-rate due to the small branching ratio for positron emis-
sion, several other factors may contribute to the difficulty of 90 Y
PET imaging. These factors can be broken into two broad cat-
egories: those associated with the low true-coincidence rate and
those associated with the high singles rate due to bremsstrahlung
X-rays. These issues are introduced here and discussed through
the remainder of this article.
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THE LOW TRUE-COINCIDENCE RATE
The low true-coincidence rate in 90 Y PET imaging results in long
scan times and noisy images, which are expected challenges given
the low branching ratio for 90 Y positron emission (11). Addi-
tionally, there are also several less obvious challenges associated
with the low true-coincidence rate. Modern PET/CT scanners use
detectors composed primarily of either cerium-doped lutetium
yttrium orthosilicate (LYSO) or cerium-doped lutetium orthosil-
icate (LSO). LYSO has become the scintillator of choice for state-
of-the-art PET systems, especially as TOF becomes standardized
due to both a superior energy resolution to bismuth-germanate
(BGO) and a light emission decay rate, which is nearly an order
of magnitude faster. Both LSO and LYSO contain lutetium which,
based on natural isotopic abundance contains 2.59% 176Lu (13).
176Lu beta decays with a long half-life, emitting several prompt
gamma rays, one of which has an energy of 401 keV. This 401-keV
gamma ray falls within the typical PET energy window result-
ing in the introduction of a low background randoms rate. The
typical true-coincidence count-rates associated with conventional
PET radiotracers are orders of magnitude higher than that cre-
ated by the presence of natural 176Lu, thus allowing this intrinsic
radioactivity to be effectively ignored. Unfortunately, this may not
be the case for 90 Y PET imaging and this intrinsic activity could
have implications affecting both the accuracy of quantification
and image quality.
BREMSSTRAHLUNG X-RAYS
The infused 90 Y dosage in radioembolization can range anywhere
from 1 to 4 GBq, and all of this activity can easily be within the axial
field of view (FOV) of a single PET bed position. Since every decay
of 90 Y emits a high-energy β, a large fluence of bremsstrahlung
X-rays can be produced. In fact, in 90 Y PET imaging the sin-
gles count-rate from bremsstrahlung exceeds the true-coincidence
count-rate by a large margin. The 90 Y bremsstrahlung energy
spectrum is broad (21) and produces the highest photon yield
at energies below 20 keV. Fortunately, the majority of these low-
energy photons are likely to be significantly attenuated by the
patient. The spectrum of released photons is relatively constant
from 20 to 500 keV, at which point the yield drops appreciably up
to its maximum of 2.28 MeV (21). One potential issue associated
with this high fluence of bremsstrahlung photons is the possibility
of detector saturation.
Detector saturation due to the high singles rate from
bremsstrahlung X-rays was initially thought to be a major barrier
associated with 90 Y PET/CT. One of the first reports of successful
clinical 90 Y PET/CT imaging (12) was performed with a custom
fabricated 2.5-mm thick copper ring designed to reduce the singles
rate due to bremsstrahlung from a patient dosage of only 1.3 GBq.
Detector saturation at the dosages used in radioembolization has
the potential to degrade image quality substantially and limit the
quantitative accuracy of 90 Y PET – a major component of its
utility.
IMAGE QUALITY
The first reported clinical 90 Y PET/CT scan (12) qualitatively
demonstrated superior resolution to bremsstrahlung SPECT. Mul-
tiple authors have since published additional examples showing
FIGURE 1 |Transaxial profile of a 90Y line source in water with a FWHM
of 3.1 mm.
that 90 Y PET produces superior image quality when compared
to alternative methods of imaging 90 Y such as bremsstrahlung
SPECT or indirect imaging with 99mTc MAA SPECT (17–19,
22–28).
RESOLUTION
Resolution has been evaluated by a number of authors on many
PET/CT systems. For 90 Y PET, the full-width at half-maximum
(FWHM) has been reported to be anywhere between 5.0 (18) and
10.6 mm (15). Table 1 details the resolution reported in recent
publications. It should be noted that the method used to evalu-
ate resolution has varied from author to author, and this explains
some of the inconsistencies seen. For example, Bagni et al. (17)
and D’Arienzo et al. (18) both evaluated resolution on a GE Dis-
covery ST and obtained a FWHM of 6.5 and 5.0 mm, respectively.
We have evaluated the resolution of a Siemens BioGraph mCT
Flow (Siemens Medical Solutions USA, Inc., Knoxville, TN, USA)
using a 0.4-mm inner-diameter line source charged with 90 Y in a
cylindrical water scatter phantom. The line source was positioned
at isocenter. Reconstruction was performed using a 10-cm FOV
(zoom of 8), a 512× 512 PET reconstruction matrix, 1 iteration
and 21 subsets with point spread function (PSF) resolution recov-
ery (RR) and TOF. Under these conditions, the axial FWHM on
this scanner was measured to be 3.1 mm. An axial profile of the
line source from this acquisition is shown in Figure 1.
CONTRAST
van Elmbt et al. (15) presented a detailed phantom analysis of
90 Y PET contrast using a custom built phantom. van Elmbt com-
pared both the hot and cold contrast of varying size hot-spheres
when filled with standard clinical activity concentrations in the
spheres and background as a function of scanner type. A LYSO
scanner (Philips Gemini TF, with and without TOF), a GSO scan-
ner (Philips Gemini power 16), and a BGO scanner (Siemens
ECAT Exact HR+) were all compared. Contrast was measured
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for effective scan times of 12, 24, 36, and 48 min on each scanner.
The LYSO-based system with TOF produced the best hot contrast,
regardless of scan time and/or sphere diameter. Results were some-
what different for cold contrast, where the intrinsic radioactivity
of 176Lu adds to cold-sphere background and reduces nominal
contrast when TOF was not used. The use of TOF compen-
sated for some of this lost cold-sphere contrast, improving LYSO
scanner performance. The BGO scanner was a poor performer,
with a 40% loss of contrast for all sphere sizes and scan times,
when both hot and cold spheres were analyzed (15). However,
D’Arienzo et al. (18) was successful at using a BGO-based system to
obtain contrast recovery exceeding 0.5 for 18 mm or larger spheres.
D’Arienzo’s findings are similar to other publications where LSO
and LYSO-based scanners were used (16, 19, 29).
Direct comparisons between 90 Y PET/CT and bremsstrahlung
SPECT using identical scan time and similar reconstruction para-
meters have also been performed. Elschot et al. (19) reported
contrast recovery to be significantly higher for phantom hot-
spheres of all sizes using PET/CT on a Siemens mCT with TOF
and RR when compared with a Siemens Symbia T16 with RR.
In many cases, the contrast recovery produced using PET/CT
exceeded bremsstrahlung SPECT by a factor of three or more.
However, the 90 Y PET images had significantly more noise. In
order to compare 90 Y PET and bremsstrahlung SPECT images
with similar noise characteristics, reconstruction parameters of
one iteration with a 15-mm Gaussian filter were applied to the PET
data, producing similar noise to the bremsstrahlung SPECT. In
this case, 90 Y PET still produced superior contrast (19). Elschot’s
quantitative comparison of contrast recovery between PET and
bremsstrahlung SPECT is in agreement with published patient
results (17, 18, 23–28), which demonstrate this qualitatively.
van Elmbt et al. (15) analyzed PET/CT scans of a phantom
filled with either 90 Y or 18F and found that the scatter fractions
were nearly identical. Despite this finding, contrast recovery with
18F is still superior to 90 Y (15, 16, 19, 26). A clear, detailed analysis
of this phenomenon is currently not present in the 90 Y PET lit-
erature, however there are several plausible explanations. The first
can be attributed to the effect of high image noise on ordered-
subset expectation maximization (OSEM) image reconstruction.
Traditional OSEM reconstruction algorithms have an inherent
non-negativity constraint, which may introduce a positive bias
in low-count portions of the image. This same issue is present
in dynamic PET where individual frames have high noise and
special reconstruction methods are used to improve quantifica-
tion and contrast recovery (30, 31). Another potential explanation
for loss of contrast recovery is the possibility of pair-production
events in the PET detector blocks from bremsstrahlung photons
that exceed 1.022 MeV. van Elmbt et al. (15) suggested that these
true-coincidence events may affect the ends of the profile tails of
the rebinned sinograms. These pair-production events may have
an impact on the scaling of the scattered sinogram to the emis-
sion sonogram and may impact randoms correction. Both of these
phenomenon require future exploration as they relate to 90 Y PET.
NOISE
Yttrium-90 PET/CT images are inherently noisy due to the small
positron emission branching fraction of 90 Y. Long clinical scan
FIGURE 2 |Yttrium-90 PET/CT following radioembolization. Note the
non-uniformity present in the hepatic parenchyma (arrow).
times of up to 45 min have been used to compensate for low
true-coincidence rates in an effort to improve image quality (32).
However, other authors have obtained acceptable image quality
with scan times as short as 20 min (22). Further, while image qual-
ity may not be acceptable for clinical interpretation, dosimetry can
be performed with scan times as low as 15 min (33).
The appearance of noise in clinical 90 Y imaging is often worse in
the non-target hepatic parenchyma where the 90 Y activity concen-
tration is lower, as illustrated in Figure 2. Although this low-level,
clustered non-target activity is often attributed to quantum mot-
tle, evidence suggests that this may represent a true physiologic
phenomenon that can be visualized with PET/CT due to its high
spatial resolution. Kennedy et al. (34) first observed clustering of
microspheres in the pathologic analysis of four explanted livers fol-
lowing radioembolization. More recently, Walrand et al. (35) has
provided simulation data supporting Kennedy’s findings using a
virtual arterial tree model to simulate asymmetrical microsphere
distribution.
QUANTIFICATION
LINEARITY
Following Lhommel’s et al. (12) first report of successful clini-
cal 90 Y PET/CT imaging with the use of a 2.5-mm thick copper
attenuating ring to prevent detector saturation, it was thought
that saturation might be the most significant factor preventing
accurate quantification of 90 Y using PET/CT. However, since this
initial report, numerous authors have presented results verify-
ing count-rate linearity at the high activity levels common in
radioembolization.
Detector saturation and non-linearity at clinical activities does
not occur in PET systems that use detector blocks composed of
LSO (16), LYSO, or GSO (15) due to their fast response time.
Further, Lhommel followed up his initial report with a publica-
tion detailing count-rate linearity up to an activity of 2.2 GBq on
the same scanner where a copper attenuator was initially used
(13). On the far end of the spectrum, Willowson et al. (16) found
excellent linearity up to an activity of 4.7 GBq on a Siemens Bio-
Graph mCT. The limited geometric efficiency of PET due to solid
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angle is a major contributor to the lack of detector saturation.
However, although bremsstrahlung SPECT has a higher geometric
efficiency than PET, the poor efficiency of its collimator prevents
saturation (15).
While a number of authors have found no evidence of detector
saturation on LSO, LYSO, and GSO scanners, there is some con-
troversy regarding saturation on BGO scanners. van Elmbt et al.
(15) found evidence of non-linearity at activities >1.2 GBq on
a Siemens Exact HR+ BGO PET system. Similarly, Walrand et al.
(36) found detector saturation on a BGO system at activities above
1.5 GBq. van Elmbt concluded that BGO-based scanners are not
suitable for 90 Y quantification, not due just to count-rate linearity
issues but also the resultant 40% loss of hot contrast at clinical
activity concentrations (15). However, it should be noted that the
scanner used by van Elmbt et al. (15) was antiquated (Table 1) and
newer BGO systems have shown to produce better results. Bagni
et al. (17) found no evidence of saturation on a GE Discovery
ST BGO PET system up to a total activity of 2.0 GBq. Similarly,
D’Arienzo was able to obtain quantifiable images using a GE Dis-
covery ST BGO scanner accurate to within 7.62% (18). Bagni et al.
results suggest that some BGO detector systems may be acceptable
for imaging many radioembolization procedures.
Table 1 details the maximum activity where count-rate linearity
was found in several recent phantom studies, stratified by scanner
type.
INTRINSIC RADIOACTIVITY
The effect of intrinsic 176Lu radioactivity has been evaluated by
assessing count-rate linearity and quantification accuracy at low
total activity within the FOV. Goedicke et al. (33) found reasonable
count-rate linearity on an LYSO-based system at total activities
from 200 to 55 MBq (<16% error), suggesting that 176Lu pro-
vides a definite but not overwhelming contribution. Kao et al.
(20) performed 15 phantom scans using available source vials with
activities ranging from 3.5 MBq to 3.2 GBq placed in an acrylic
scattering phantom. Across all imaged activities, the mean relative
error in 90 Y PET quantification was 1.38% while vial activities
exceeding 400 MBq had a mean error of only 0.29%. However,
these analyses may not have been clinically realistic as they were
performed using a decaying 90 Y source vial with a very small vol-
ume, preventing evaluation of activity concentration. While the
total activity within the FOV was low, the activity concentration
still may have been quite high.
Carlier focused on identifying the minimum detectable activity
concentration (MDA) of 90 Y PET/CT (26). The MDA for a 10-mm
hot-sphere in a 40:1 hot-sphere to background activity concen-
tration was found to be ~1 MBq/mL with TOF and 3 MBq/mL
without TOF. Spheres larger than 17 mm were detected at the
lowest activity concentration imaged (0.49 MBq/mL). Similarly,
Willowson et al. (16) found accurate quantification of large spheres
and total activity within the FOV at activity concentrations as low
as 0.380 MBq/mL. A study by Kao et al. (20) further corroborated
these findings.
While accurate quantification at activity concentrations com-
mon in 90 Y radioembolization have been reported, one author
designed a protocol specifically to quantify and subtract the sig-
nal resulting from intrinsic 176Lu activity (37). Using a two-step
process, patients received a PET/CT scan both before and after
the infusion of 90 Y using the same acquisition protocol. The
pre-treatment scan served as a measurement of the background
contribution from intrinsic 176Lu activity, allowing for later back-
ground subtraction. Data from an example patient presented
showed an average pre-treatment activity concentration in the
liver to be 29.6 Bq/mL, resulting from intrinsic 176Lu activity on
a Siemens BioGraph 16 Truepoint PET/CT system. Interestingly,
the average background found was significantly less than the typ-
ical tumor activity concentration in radioembolization, which is
often >2 MBq/mL. This likely explains why other authors were
able to obtain quantifiable results without the use of background
subtraction.
RECONSTRUCTION
Several publications have investigated optimal OSEM reconstruc-
tion parameters for quantifying 90 Y PET/CT. An in-depth analysis
by Willowson et al. (16) examined the effect of reconstruction
parameters on quantitative accuracy as a function of both hot-
sphere size and activity concentration using the IEC NEMA Body
Phantom. This phantom was initially imaged with a hot-sphere
activity concentration of 3.9 MBq/mL and a background concen-
tration of 0.47 MBq/mL. It was then serially imaged at multiple
time points down to hot-sphere and background concentrations of
0.380 and 0.037 MBq/mL, respectively. Regardless of activity con-
centration or hot-sphere size, reconstruction parameters of 1 iter-
ation and 21 subsets with TOF and RR provided the most accurate
quantification on a Siemens BioGraph mCT. Carlier et al. (26) also
performed a similar analysis and corroborated the conclusion that
one iteration provides the most accurate quantification. It is likely
that optimal reconstruction techniques are scanner-dependent as
both Willowson and Carlier performed their analysis on Siemens
BioGraph mCT systems, while D’Arienzo found two iterations to
be optimal on a GE Discovery ST system (18). Goedicke et al.
(33) used a Philips Gemini TF 16 system and found that the
number of reconstruction subsets had a dominant effect on quan-
titative accuracy in both hot and cold regions, concluding that 2
iterations and 60 subsets was optimal. However, Goedicke noted
that large numbers of subsets had the effect of increased noise
clustering, perhaps negatively effecting uniformity or producing
reconstruction-related artifacts.
There is overwhelming evidence in the literature to suggest that
90 Y PET is a quantifiable with a reasonable degree of accuracy.
In all reported instances, neither detector saturation nor intrinsic
176Lu radioactivity substantially affected accurate quantification at
activity concentrations common in radioembolization on modern
scanners using LSO or LYSO detectors. Careful selection of recon-
struction parameters can increase quantitative accuracy, however,
the best choice will depend on the scanner and reconstruction
software.
90Y PET/CT DOSIMETRY
The complexity of techniques for radioembolization treatment-
planning and post-infusion dosimetry has grown significantly
in the past 10 years. Beginning with the MIRD schema for 90 Y
hepatic radioembolization (38), there has been an effort to esti-
mate the dose to the tumor independently from the dose to
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the normal hepatic parenchyma. From compartmentalized mod-
els (38, 39), research in radioembolization has moved in the
direction of 3-dimensional (3D) absorbed dose maps, which can
be utilized for analysis of dose–volume histograms (DVH) and
comparison of tumor-absorbed dose with known tumoricidal
thresholds.
Image-based dosimetry for radioembolization has been per-
formed in 3D using dose-point-kernel (DPK) convolution, with
or without the use of 90 Y PET/CT. Both Kennedy et al. (40) and
Dieudonne et al. (41) have used 3D SPECT data following infu-
sion of 99mTc MAA translated into absorbed dose maps using DPK
convolution. A number of authors have used DPK convolution as
a tool to compute absorbed dose in patient and phantom stud-
ies using post-infusion imaging with 90 Y PET/CT (13, 18, 19, 32,
37, 42). In several cases, DPKs were used from published litera-
ture such as reported by Strigari et al. (43) or Lanconelli et al.
(44). However, because the DPK voxel size must match the PET
acquisition matrix voxel size, DPKs were often calculated for spe-
cific scenarios using Monte Carlo radiation transport codes. Many
Monte Carlo codes have been used in the 90 Y PET literature for
this purpose including EGSnrc (40, 45), MCNP-X (19, 46), and
FLUKA (37, 47).
Unlike other forms of targeted internal radionuclide therapy,
radioembolization has the benefit of negligible biological removal
following infusion. On that premise, absorbed dose following 90 Y
radioembolization can be calculated by 3D convolution of the 3D
activity concentration matrix with the β-DPK for 90 Y. Eq. 1 below
describes this process:
D
(
x , y , z
) = 1
λ
(A ⊗ DPK) (x , y , z)
= 1
λ
∑
z ′
∑
y ′
∑
x′
A
(
x′, y ′, z ′) ∗ DPK
× (x − x′, y − y ′, z − z ′) (1)
where λ is the decay constant of 90 Y, A represents the 3D activ-
ity concentration voxel space and DPK is the computed DPK
per disintegration of 90 Y. In the reports cited above, the activ-
ity concentration matrix was taken from 90 Y PET/CT data. DPK
convolution can be performed in a clinical setting using software
such as the popular FDA approved MIDose code by DOSIsoft
(Dosisoft, Cachan, France).
One alternative technique to DPK convolution that has been
used in several 90 Y PET publications is a method whereby energy
from 90 Y β-decay is deposited locally, within each voxel and no
convolution is used. While this method may initially appear to
be less accurate than DPK convolution, one must consider that
the activity concentration matrix determined by PET/CT is not
precisely A in Eq. 1, but rather A convolved with the PSF of the
PET/CT system. On this premise, both Kao et al. (20) and Bour-
geois et al. (48) have performed 3D dosimetry without using DPK
convolution, under the assumption that the PSF of the PET/CT
system approximates the 90 Y β-DPK. Kao et al. (20) presented
justification for his technique in an included appendix,while Bour-
geois et al. (48) cited a prior publication, which validated this
method for SPECT (49).
CLINICAL UTILITY OF POST-TREATMENT 90 Y PET/CT
IMAGING
90 Y PET/CT imaging following radioembolization serves in two
primary clinical roles: (1) evaluating technical success and (2)
predicting treatment efficacy.
EVALUATION OF TECHNICAL SUCCESS
Successful radioembolization requires microsphere delivery
within the target hepatic lobe and/or lesions selected for therapy.
Although the primary goal of radioembolization is straightfor-
ward in principle, numerous procedural and physiologic factors
contribute to, and potentially confound technical success. These
include patient factors such as variable arterial hemodynamics
and tumor vascularity, as well as technical factors such as catheter
position, total particulate load delivered, and rate of microsphere
delivery.
Technical success with 90 Y trans-arterial hepatic embolization
has traditionally been assumed by successful infusion of 90 Y into
the target artery and bremsstrahlung SPECT demonstrating activ-
ity in the region of the targeted hepatic lobe. However, accurate
confirmation of pre-treatment radiation-planning intentions was
not possible using conventional bremsstrahlung SPECT, as illus-
trated in Figure 3. Figure 3A shows the pre-treatment hepatic
protocol CT obtained on a patient with metastatic cholangio-
carcinoma in the left lobe. The neoplasm is characterized by
central necrosis surrounded by peripheral contrast-enhancing
viable tumor. The left hepatic arteriogram in Figure 3B con-
firms infusion of SIRTeX SIR-Sphere® radioembolization into the
target artery. Finally, the post-treatment bremsstrahlung SPECT
in Figure 3C demonstrates diffuse activity in the region of the
left lobe hepatic neoplasm. However, due to the limited res-
olution of bremsstrahlung SPECT, a detailed comparison with
pre-treatment imaging was not possible. The post-treatment
90 Y PET/CT in Figure 3D demonstrates more detailed infor-
mation with multifocal areas of maximum activity correspond-
ing to the peripheral viable tumor seen on the pre-treatment
hepatic CT.
Lack of technical success can also be identified using 90 Y
PET/CT with high specificity. Historically, lack of technical suc-
cess would not be apparent until delayed conventional imaging
and clinical follow-up determine poor success in tumor manage-
ment. Identification of technical failure on 90 Y PET/CT imaging
gives the opportunity for treating physicians to consider addi-
tional therapies before discovering clinical failure weeks to months
later. Alternative or supplemental therapies such as trans-arterial
drug eluting bead embolization or percutaneous thermal abla-
tion may be considered in a timely manner. Figure 4 illustrates
an example of technical failure as compared to pre-treatment
radioembolization therapy-planning intent. Figure 4A is a pre-
treatment 18FDG PET/CT with conspicuous tumor activity in
the left hepatic lobe. Technical success was initially inferred from
successful infusion of the SIRTeX SIR-Sphere® radioembolization
dosage into the left hepatic artery, and presence of left lobe activity
on the post-treatment 90 Y bremsstrahlung SPECT scan. How-
ever, the 90 Y PET/CT following radioembolization demonstrated
lack of significant uptake in the region of most active tumor
(Figure 4B). A detailed description of 90 Y PET/CT diagnostic
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FIGURE 3 | (A) Pre-treatment contrast enhanced CT imaging of metastatic
cholangiocarcinoma in the left hepatic lobe. Areas of increased vascularity
(arrow) are seen surrounding areas of necrosis. (B) Left hepatic angiogram
during infusion of 90 Y into left lobe. (C) Bremsstrahlung SPECT following
radioembolization demonstrates diffuse activity in the region of the left lobe
hepatic neoplasm. (D) 90 Y PET/CT demonstrates more detailed information
with multifocal areas of maximum activity corresponding to the peripheral
viable tumor on pre-treatment imaging.
reporting, including many more examples has been presented
by Kao et al. (27). Many other reports have recently presented
results and example cases comparing bremsstrahlung SPECT post-
treatment images with 90 Y PET/CT images, illustrating quali-
tatively superior resolution and contrast with 90 Y PET/CT (12,
22–26, 28).
QUANTITATIVE PREDICTION OF TREATMENT EFFICACY
90 Y PET/CT equips treating physicians with precise information
regarding the heterogeneity of microsphere distribution within
a lesion and the absorbed radiation dose to each part of the
lesion. These factors could be helpful in predicting treatment
response or the need for early triage to alternative or adjuvant
therapy. Several authors have used 90 Y PET-based dosimetry to
predict treatment response in patients receiving radioemboliza-
tion (18, 20, 32, 42, 48). However, while there are standardized
and accepted methods for generating 3D absorbed dose maps
from 90 Y PET/CT data, there is no standardization of the dose
metric used to predict treatment response in radioembolization
patients.
Chang et al. (32), Bourgeois et al. (48), and D’Arienzo et al.
(42), all used the average absorbed dose to the lesion (Davg). In an
article by Bourgeois et al. (48), Davg was selected to coincide with
one of the largest published patient studies detailing radiobiologic
toxicity of SIRTeX SIR-Sphere® radioembolization in hepatocellu-
lar carcinoma (HCC) (50). Alternatively, Kao et al. (20) used D70
and V 100 values for tumor analysis, where D70 and V 100 are the
minimum absorbed dose delivered to 70% of the tumor volume
andV 100 is the percentage of tumor volume exceeding 100 Gy. Kao
et al. (20) outlines several applicable external beam radiotherapy
standards which could be applied to 90 Y radioembolization.
The missing component for the accurate prediction of treat-
ment efficacy using 90 Y PET/CT following radioembolization
is a detailed compendium of radiobiologic toxicities. The ideal
minimum requirements for such a database would include dose–
response data that is stratified by the type of radioembolization
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FIGURE 4 | (A) 18FDG PET/CT showing large focal lesion from
metastatic cholangiocarcinoma prior to radioembolization (arrow).
This was the only conspicuous lesion in this patient’s left lobe.
(B) 90 Y PET/CT following radioembolization. Poor tumor uptake can be
seen (T/N <1) with the majority of the dosage distributing to non-target
areas of the left lobe.
used (i.e., SIRTeX SIR-Spheres® or BTG ThereSpheres®) and the
type of tumor being treated. However, no such database currently
exists. Strigari has published (50) an excellent database compiled
from 73 patients treated for HCC with SIRTeX SIR-Spheres® and
her data remains one of the most complete offerings in the current
literature. However, because 90 Y PET/CT can provide quantitative
post-treatment imaging, it is likely that more dose–response data
will be available in the near future. As these data become avail-
able, clinicians who choose to use it along with post-treatment
Y90 PET to predict treatment efficacy or modify treatments (as
described in the next section) must be particularly cautious that
the referenced dose–response data is appropriate for the clinical
case. For instance, application of Strigari’s dose–response data (50)
to the clinical decision making process for a patient treated with
BTG ThereSpheres® would be contraindicated. While 90 Y PET can
quantify absorbed dose from SIRTeX SIR-Spheres® or BTG There-
Spheres® with equal accuracy, due to the activity per microsphere
as well as the number of microspheres used, the dose–response
relationship between the two products is significantly different.
90 Y PET/CT IMAGING AS A TOOL FOR IMPROVING
TREATMENT
In addition to confirmation of technical success and prediction
of treatment efficacy, 90 Y PET/CT imaging has the potential to
prospectively improve therapy. Recent reports explore two mech-
anisms by which 90 Y PET/CT can be used to directly tailor
treatment-planning for radioembolization.
The current advanced method of 90 Y treatment-planning
involves use of 99mTc MAA as a microsphere surrogate. The
partition model (39) is used clinically as a radioembolization
treatment-planning tool at many sites based on the measurement
of T/N on 99mTc MAA SPECT imaging. However, factors includ-
ing differences in catheter position, embolic load, particle size,
injection technique, free 99mTc, and physiologic changes occurring
between MAA and radioembolization procedures may affect the
accuracy of MAA as a microsphere surrogate. Knesaurek et al. (51)
suggested that these factors explained varying agreement found
between the hepatic distribution of MAA and radioembolization
in a 20-patient study. Wondergem et al. (52) also reported poor
correlation between MAA and 90 Y distribution. However, Kao
et al. (20) found good agreement between dosimetry based on
99mTc MAA and 90 Y PET.
While debate on the effectiveness of MAA as a radioemboliza-
tion surrogate still exists, several recent reports have incorporated
90 Y PET/CT into treatment-planning algorithms to optimize ther-
apy without relying on 99mTc MAA SPECT imaging. Chang et al.
(32), presented a report where a patient received two separate
SIRTeX SIR-Sphere® radioembolization treatments for cholan-
giocarcinoma metastases in the right and left hepatic lobes. The
SIRTeX body surface area (BSA) treatment-planning model was
used for the treatment of the right hepatic lobe lesion. Follow-
ing the first treatment, 90 Y PET indicated that the absorbed dose
to the right lobe tumor was <70 Gy with a T/N measuring just
2.5:1. Subsequent radioembolization of a lesion in the left hepatic
lobe was performed with treatment-planning based on the parti-
tion model (39) and the T/N measured from the 90 Y PET/CT of
the right lobe. Another 90 Y PET/CT performed after the left lobe
treatment indicated a tumor-absorbed dose of 110 Gy. Follow-up
imaging demonstrated no response in the right lobe lesion and
complete response in the left lobe (32).
While debate exists on the effectiveness of MAA as a radioem-
bolization surrogate, one can conclude that Chang’s method
(32) did eliminate some uncertainties in that it did not rely on
MAA. However, Chang applied measurements from focal dis-
ease in one lobe to treat focal disease in another lobe, which
has unproven validity (32). A subsequent report by Bourgeois
et al. (48) described results from a patient with HCC who under-
went a novel dual-infusion, single-day radioembolization protocol
using SIRTeX SIR-Spheres®. An initial 90 Y infusion was performed
using a conventional treatment-planning model, followed by 90 Y
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PET/CT. A 3D absorbed dose map was generated from 90 Y PET,
which allowed for quantification of a tumor-absorbed dose of
53.2 Gy. A simple arithmetic proportion was then applied to deter-
mine the necessary additional 90 Y dosage required to achieve
a total tumor-absorbed dose of 120 Gy, corresponding to pub-
lished recommendations for HCC (50). The additional dosage was
delivered in the same day, with comparable catheter placement
and resulted in a robust treatment response (48). The benefit to
Bourgeois’ protocol was that it provided patient-specific radioem-
bolization treatment-planning, however, the complexity of the
protocol may limit clinical use.
There may be utility in adapting Bourgeois’ protocol (48) as
part of a multi-cycle fractionated radioembolization treatment
method, previously discussed by Cremonesi et al. (53). This would
allow patient-specific treatment-planning to be combined with
increased sparing of normal liver parenchyma, increased dose
to the tumor, and may be a potential future application of 90 Y
PET/CT.
IMPROVING 90 Y PET/CT IMAGING
Multiple authors have found excellent quantification, resolution,
and contrast recovery in 90 Y PET/CT phantom studies. However,
there is still potential for improving both quantitative accuracy
and image quality in 90 Y PET/CT. As previously discussed, con-
trast recovery for 90 Y PET is less than 18F PET. Because the
scatter fractions have been found to be nearly identical (15) for
18F and 90 Y, it is likely that the differences in contrast recovery
may be attributed to the effects of image noise on conventional
reconstruction algorithms. Standard clinical OSEM reconstruc-
tion algorithms contain an inherent non-negativity constraint,
which is appropriate for conventional radiotracers where image
noise is low. However, this non-negativity constraint can con-
tribute to a positive bias in 90 Y PET images, particularly in the
low-count background resulting in a decrease in contrast recov-
ery. A similar issue has been found in dynamic PET, where short
duration frames contribute to high image noise resulting in a
positive bias when conventional OSEM is used (30). NEG-ML
(54) and AB-EM (55) are two reconstruction algorithms with-
out non-negativity constraints that have been used to address
this issue in dynamic PET. Verhaeghe and Reader (30) have
compared both algorithms, and while either improves quantifica-
tion accuracy in dynamic PET compared to conventional OSEM,
AB-EM produced the best results. Application of these tech-
niques to 90 Y PET may, therefore, provide a benefit. However,
widespread use will likely require direct support from PET/CT
manufacturers.
Another area where 90 Y quantification can be improved is with
application of gated acquisition protocols. Several studies have
shown a quantitative improvement with gated 18FDG PET. Lupi
et al. (56) performed non-gated and gated PET/CT studies in
22 patients with lung carcinoma. Gating resulted in a maximum
average increase of 77% in the SUV of measured lesions. Werner
et al. (14) evaluated the effect of respiratory gating during 18FDG
PET/CT on estimation of lesion size and SUV in 18 patients with
pulmonary nodules and found a 22% maximum average increase
in SUV, as well as a decrease in nodule volume by 44.5%. Gating
has also shown to be useful for 18FDG PET/CT imaging of liver
metastases, mirroring results from chest studies with statistically
significant increases in SUV with the use of a respiratory-gated
protocol (57). However, traditional phase-based gating used in
PET is based on principles applied to cardiac gating, where a
temporal description of motion is useful for diagnosis. The PET
dataset is divided into multiple temporal bins with the phase of the
breathing cycle. This process results in a significant decrease in the
number of counts contributing to each image or bin, increasing
image noise. Due to the low true-coincidence count-rate associ-
ated with 90 Y PET, phased-based gating is not a viable option
since the resulting images would be too noisy to be quantitatively
or diagnostically useful.
Amplitude-based gating is an alternative to phase-based gat-
ing first described in 4D-CT by Rietzel et al. (58) and further
refined to account for motion by Wink et al. (59). This method uses
amplitude information rather than temporal information to sort
the reconstructed data. Amplitude-based methods were applied to
PET/CT imaging by Wang et al. (60), who described the perfor-
mance of this type of algorithm in controlled phantom studies.
This gating method is useful in PET/CT imaging as it retains more
counts than phase-based gating with the trade off of a loss of a
temporal description of motion.
A method of amplitude-based gating, known as optimal res-
piratory gating, was developed in 2010 by Hamill et al. and
patented in 2011 (61). This method uses an upper and lower
threshold pair correlated to a measured respiratory signal to cre-
ate an optimally gated static PET image that corresponds to the
phase of the respiratory cycle where motion is at a minimum.
In recent work, the authors of this manuscript have performed
90 Y PET/CT scans with continuous bed motion acquisition tech-
niques (FlowMotion) in conjunction with optimal respiratory
gating (HD-Chest) using a Siemens BioGraph mCT Flow (Siemens
Medical Solutions USA, Inc., Knoxville, TN, USA). Initial results
show decreases in visualized tumor volume and increases in
90 Y activity concentration with the use of optimal respiratory
gating techniques. Figures 5A,B qualitatively illustrate the dif-
ference between an acquisition performed on a Siemens Bio-
Graph mCT Flow with TOF and RR, with and without HD-
Chest. Using automatic contouring with the same threshold,
visual tumor volume decreased by 33% when optimal respira-
tory gating is used, along with increases in average and maxi-
mum activity concentration. Scan times on the order of 25 min
produce acceptable image quality, even with the gated protocol
(Figure 5B).
CONCLUSION
90 Y PET/CT is a tool that has the potential to contribute sig-
nificantly toward improving radioembolization in the future.
Accurate quantification of activity concentration has been demon-
strated on a variety of PET/CT systems, with or without TOF.
Further, methods are available to transform 90 Y PET image sets
into 3D absorbed dose maps in the setting of a traditional clin-
ical workflow. In fact, many institutions with a modern PET/CT
system are currently fully equipped to perform post-treatment
90 Y PET/CT scans and generate absorbed dose maps. Not only
will post-treatment 90 Y PET/CT allow treating physicians to more
appropriately manage the care of their patients, but also increasing
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FIGURE 5 | (A) 90 Y PET of a patient with HCC. Scan performed on Siemens
BioGraph mCT Flow withTOF and RR. A continuous bed speed of 0.2 mm/s, 1
iteration, and 21 subsets were used for reconstruction. The contour (red) was
performed by an automatic segmentation tool with the lower threshold set to
an absorbed dose of 100 Gy. (B) 90 Y PET of a patient with HCC. Scan
performed on Siemens BioGraph mCT Flow with TOF, RR, and optimal
respiratory gating (HD-Chest). A continuous bed speed of 0.2 mm/s, 1
iteration, and 21 subsets were used for reconstruction. The contour (red) was
performed by an automatic segmentation tool with the lower threshold set to
an absorbed dose of 100 Gy.
utilization of 90 Y PET has the potential to provide a wealth of
dose–response information. This information may lead to the
development of improved radioembolization treatment-planning
models in the future.
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